Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.73 |
| ▸ | DRD4 | P21917 | 17/20 | 0.73 |
| ▸ | DRD3 | P35462 | 17/20 | 0.73 |
| ▸ | HTR2A | P28223 | 14/20 | 0.73 |
| ▸ | DRD1 | P21728 | 12/20 | 0.73 |
| ▸ | DRD5 | P21918 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606548 | 0.90 | DRD2 (0.68) | DRD2DRD4DRD3HTR2ADRD1 | |
| SCHEMBL3613055 | 0.90 | DRD2 (0.72) | DRD2DRD4DRD3HTR2ADRD1 | |
| SCHEMBL3615975 | 0.85 | DRD2 (1.00) | DRD2DRD4DRD3HTR2ADRD1 | |
| SCHEMBL3618867 | 0.82 | DRD2 (0.93) | DRD2DRD4DRD3HTR2ADRD1 | |
| SCHEMBL3606567 | 0.81 | DRD2 (0.66) | DRD2DRD4DRD3HTR2ADRD1 | |
| SCHEMBL3611189 | 0.81 | DRD2 (0.88) | DRD2DRD4DRD3HTR2ADRD1 | |
| SCHEMBL3610425 | 0.81 | DRD2 (0.65) | DRD2DRD4DRD3HTR2ADRD1 | |
| SCHEMBL3652955 | 0.81 | DRD4 (0.50) | DRD2DRD4DRD3HTR2ADRD1 | |
| SCHEMBL3617535 | 0.81 | DRD2 (0.62) | DRD2DRD4DRD3HTR2ADRD1 | |
| SCHEMBL3613900 | 0.79 | DRD2 (1.00) | DRD2DRD4DRD3HTR2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | DONSBACH, MARTIN (DE) | 2010-07-01 | — | — | US | claimed |
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | DONSBACH, MARTIN (DE) | 2010-07-01 | — | — | US | disclosed |
| EP-1972628-A1 | Indolizines and aza-analog derivatives thereof as CNS active compounds | SCHWARZ PHARMA AG (DE) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | INMT, AANAT, AZI2 | DRD2 123/4885DRD4 133/4885DRD3 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.